Asif Ali compensation by year
Protagonist Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $447,000 | $465,000 | $500,000 |
| Bonus | $0 | $55,800 | $0 |
| Stock awards | $129,306 | $491,820 | $1,238,745 |
| Option awards | $641,867 | $1,514,011 | $1,192,502 |
| Non-equity incentive | $178,800 | $279,000 | $320,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $5,242 | $5,242 | $6,242 |
| Total | $1,402,215 | $2,810,873 | $3,257,489 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Protagonist Therapeutics, Inc DEF 14A filed April 28, 2026, accession 0001104659-26-050429, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Protagonist Therapeutics, Inc filed document, accession 0001104659-26-050429. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 31,779 | $2,775,578 | — |
| RSU | 14,001 | $1,222,847 | — |
| RSU | 3,542 | $309,358 | — |
| RSU | 3,438 | $300,275 | — |
| Option | 6,875 | — | $19.19 |
| Option | 40,625 | — | $23.42 |
| Option | 29,693 | — | $38.98 |
| Option | 17,266 | — | $12.17 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Protagonist Therapeutics, Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
10 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-30 | Sale | 10b5-1 | 12,595 | $141.77 | 105,037 |
| 2026-09-30 | Exercise or conversion | 10b5-1 | 15,650 | $19.19 | 112,320 |
| 2026-09-30 | Sale | 10b5-1 | 46,034 | $141.78 | 59,003 |
| 2026-09-30 | Exercise or conversion derivative | 10b5-1 | 9,229 | $0.00 | 29,291 |
| 2026-09-30 | Exercise or conversion derivative | 10b5-1 | 28,438 | $0.00 | 49,562 |
| 2026-09-30 | Exercise or conversion derivative | 10b5-1 | 15,650 | $0.00 | 51,150 |
| 2026-09-30 | Exercise or conversion | 10b5-1 | 9,229 | $38.98 | 68,232 |
| 2026-09-30 | Exercise or conversion | 10b5-1 | 28,438 | $23.42 | 96,670 |
The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Protagonist Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control, no termination | $0 | $0 | $0 | $0 |
| Voluntary resignation | $0 | $0 | $0 | $0 |
| Involuntary termination without cause | $375,000 | $0 | $31,550 | $406,550 |
| Change in control and involuntary termination | $500,000 | $10,407,178 | $42,066 | $11,149,244 |
Per the Potential Payments Upon Termination or Change in Control table in Protagonist Therapeutics, Inc's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Protagonist Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Dinesh Patel | President and Chief Executive Officer | $12,871,506 |
| Arturo Molina | Chief Medical Officer | $4,095,230 |
| Asif Ali · this page | Executive Vice President, Chief Financial Officer | $3,257,489 |
Board service
Protagonist Therapeutics board · FY2022How this board is paid
Company policy: Protagonist Therapeutics pays directors a $40,000 cash retainer and $20,000 in Options. As stated in Protagonist Therapeutics's FY2022 proxy.
Asif Ali's compensation dossier, Protagonist Therapeutics
You have read Asif Ali's totals and holdings. The dossier adds each equity grant Protagonist Therapeutics disclosed for Asif Ali and Protagonist Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Protagonist Therapeutics compensation record
free company briefThis page is one person within Protagonist Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Protagonist Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Protagonist Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Protagonist Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order PTGX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.